These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 38603866)
1. BRAF mutations and survival with surgery for colorectal liver metastases: A systematic review and meta-analysis. Petrelli F; Arru M; Colombo S; Cavallone M; Cribiu' FM; Villardita V; Floris P; Digiesi L; Severgnini G; Moraes MT; Conti B; Celotti A; Viti M; Sozzi A Eur J Surg Oncol; 2024 Jun; 50(6):108306. PubMed ID: 38603866 [TBL] [Abstract][Full Text] [Related]
2. Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis. Passiglia F; Bronte G; Bazan V; Galvano A; Vincenzi B; Russo A Crit Rev Oncol Hematol; 2016 Mar; 99():150-7. PubMed ID: 26775732 [TBL] [Abstract][Full Text] [Related]
3. The challenge of molecular selection in liver-limited metastatic colorectal cancer for surgical resection: a systematic review and meta-analysis in the context of current and future approaches. Roncato R; Polesel J; Tosi F; Peruzzi E; Brugugnoli E; Pantano CL; Furfaro M; Girolamo FD; Nani A; Pani A; Milan N; DE Mattia E; Sartore-Bianchi A; Cecchin E Oncol Res; 2024; 32(9):1407-1422. PubMed ID: 39220128 [TBL] [Abstract][Full Text] [Related]
4. Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis. Tosi F; Magni E; Amatu A; Mauri G; Bencardino K; Truini M; Veronese S; De Carlis L; Ferrari G; Nichelatti M; Sartore-Bianchi A; Siena S Clin Colorectal Cancer; 2017 Sep; 16(3):e153-e163. PubMed ID: 28216246 [TBL] [Abstract][Full Text] [Related]
5. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence. Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183 [TBL] [Abstract][Full Text] [Related]
6. BRAF mutation is not associated with an increased risk of recurrence in patients undergoing resection of colorectal liver metastases. Bachet JB; Moreno-Lopez N; Vigano L; Marchese U; Gelli M; Raoux L; Truant S; Laurent C; Herrero A; Le Roy B; Deguelte Lardiere S; Passot G; Hautefeuille V; De La Fouchardiere C; Artru P; Ameto T; Mabrut JY; Schwarz L; Rousseau B; Lepère C; Coriat R; Brouquet A; Sa Cunha A; Benoist S Br J Surg; 2019 Aug; 106(9):1237-1247. PubMed ID: 31183866 [TBL] [Abstract][Full Text] [Related]
7. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer. Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910 [TBL] [Abstract][Full Text] [Related]
8. Impact of BRAF mutations on clinical outcomes following liver surgery for colorectal liver metastases: An updated meta-analysis. Gau L; Ribeiro M; Pereira B; Poirot K; Dupré A; Pezet D; Gagnière J Eur J Surg Oncol; 2021 Nov; 47(11):2722-2733. PubMed ID: 34099355 [TBL] [Abstract][Full Text] [Related]
9. Reevaluating the prognostic role of BRAF mutation in colorectal cancer liver metastases. Pikouli A; Papaconstantinou D; Wang J; Kavezou F; Pararas N; Nastos C; Pikoulis E; Margonis GA Am J Surg; 2022 May; 223(5):879-883. PubMed ID: 34544580 [TBL] [Abstract][Full Text] [Related]
10. Genomic and prognostic heterogeneity among RAS/BRAF Berg KCG; Brunsell TH; Sveen A; Alagaratnam S; Bjørnslett M; Hektoen M; Brudvik KW; Røsok BI; Bjørnbeth BA; Nesbakken A; Lothe RA Mol Oncol; 2021 Apr; 15(4):830-845. PubMed ID: 33325154 [TBL] [Abstract][Full Text] [Related]
11. Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. Karagkounis G; Torbenson MS; Daniel HD; Azad NS; Diaz LA; Donehower RC; Hirose K; Ahuja N; Pawlik TM; Choti MA Cancer; 2013 Dec; 119(23):4137-44. PubMed ID: 24104864 [TBL] [Abstract][Full Text] [Related]
12. Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases. Løes IM; Immervoll H; Sorbye H; Angelsen JH; Horn A; Knappskog S; Lønning PE Int J Cancer; 2016 Aug; 139(3):647-56. PubMed ID: 26991344 [TBL] [Abstract][Full Text] [Related]
13. BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. Schirripa M; Bergamo F; Cremolini C; Casagrande M; Lonardi S; Aprile G; Yang D; Marmorino F; Pasquini G; Sensi E; Lupi C; De Maglio G; Borrelli N; Pizzolitto S; Fasola G; Bertorelle R; Rugge M; Fontanini G; Zagonel V; Loupakis F; Falcone A Br J Cancer; 2015 Jun; 112(12):1921-8. PubMed ID: 25942399 [TBL] [Abstract][Full Text] [Related]
14. Prognostic factors of BRAF V600E colorectal cancer with liver metastases: a retrospective multicentric study. Javed S; Benoist S; Devos P; Truant S; Guimbaud R; Lièvre A; Sefrioui D; Cohen R; Artru P; Dupré A; Bachet JB; de la Fouchardière C; Ploquin A; Turpin A World J Surg Oncol; 2022 Apr; 20(1):131. PubMed ID: 35461290 [TBL] [Abstract][Full Text] [Related]